Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for the prevention and treatment of allergic inflammatory disease

A technology for allergic inflammation and allergic rhinitis, applied in the direction of allergic diseases, drug combinations, anti-inflammatory agents, etc., can solve the problems of effective, ineffective, and leukotriene B4 receptor antagonist treatment, etc.

Inactive Publication Date: 2007-07-11
DONG WHA PHARM CO LTD
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The leukotriene B4 receptor antagonist ONO-4057 has also been reported to have a therapeutic effect on bronchial asthma when used in combination with the cysteinyl leukotriene receptor antagonist Zafirlukast, but was ineffective when used alone (SakuradaT et al., Eur J Pharmacol. 1999 Apr 9:370(2):153-9)
Therefore, it cannot be said that leukotriene B4 receptor antagonists are effective for the treatment of allergic inflammation including asthma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for the prevention and treatment of allergic inflammatory disease
  • Composition for the prevention and treatment of allergic inflammatory disease
  • Composition for the prevention and treatment of allergic inflammatory disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

Example: Therapeutic Effects in a Mouse Model of Asthma Induced with Ovalbumin

[0025] The curative effect of the benzamidine compound of Chemical Formula 1 on allergic inflammation in ovalbumin-induced asthma mouse model was determined. The benzamidine compound was administered for 18 consecutive days from the start of sensitization with ovalbumin. The experimental animals were re-exposed to ovalbumin 15 days after sensitization and sacrificed 3 days after this re-exposure. Changes in lung weights, cellular components in peripheral blood and bronchoalveolar sac washes, and lung histopathology were observed.

1. Experimental animals and feeding management

[0026] A total of 20 female C57BL / 6 mice (6 weeks old, BioGenomics, Korea) were acclimated to the laboratory environment for 6 days before being used in real experiments. When housed in plastic cages at a density of 5, the experimental animals were housed in a rearing room under controlled temperature (20 to 25° C.) and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein is a composition for the treatment and prevention of allergic inflammatory diseases comprising N-hydroxy-4-{5- [4- (5-isopropyl-2-methyl-l, 3-thiazol-4- yl)phenoxy]pentoxy}-benzamidine, 4-{5- [4- (5-isopropyl-2- methyl-1, 3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or pharmaceutically acceptable salts. The composition exhibits excellent medicinal effects on allergic inflammatory diseases, with a great reduction in typical chronic inflammation symptoms, such as an increase of eosinophil level in bronchoalveolar lavage fluid, total leukocyte level and eosinophil level in blood, the hypertrophy or hyperplasia of bronchial epithelium due to an increase in the number of mucus cells, a reduction in alveolar surface area resulting from the hypertrophy of alveolar walls, and the infiltration of inflammatory cells.

Description

technical field [0001] The present invention generally relates to compositions for the prevention and treatment of allergic inflammation, and more particularly to compositions comprising N-hydroxy-4-{5-[4-(5-isopropyl-2) for the prevention or treatment of allergic inflammation -Methyl-1,3-thiazol-4-yl)phenoxy]pentyloxy}-benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3- A composition of thiazol-4-yl)phenoxy]pentyloxy}-benzamidine or a pharmaceutically acceptable salt thereof. Background technique [0002] As various pathologies related to environmental pollution, stress, living environment, etc. have increased, allergic inflammation has also increased. Allergic inflammation is attributed to an abnormality of the immune system in which the nasal or bronchial mucosa or the skin is sensitized to external allergens. The basic causes of allergic reactions include stress, bleeding, etc. However, the main reason is nutritional imbalance. [0003] Depending on the site of the immune...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/426A61P37/08
CPCA61K31/426A61P11/02A61P11/06A61P17/04A61P27/14A61P29/00A61P37/08A61K31/155
Inventor 李振洙具世光李相昊柳济万
Owner DONG WHA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com